Viratek's first NDA approval, at the end of 1985, excited Wall Street for the first month of 1986. With its Virazole (ribavirin) approval in hand, the ICN subsidiary advanced 5-1/4 points in January to close at 26-1/2, a nearly 25% gain. The first antiviral approved by FDA for synctial virus-caused lower respiratory infections, the aerosol product has a target population of almost 100,000 infant and pediatric, hospitalized patients. In addition, Virazole is being examined, in conjunction with Eastman Kodak, as an agent for AIDS related complex. A multicenter, 400-patient trial is currently planned. Genentech (up 8-1/2 to 78-1/4) and Centocor (up 4 to 25-3/4) led a strong biotech group that has continued its market rally into the new year. Out of eleven biotech issues on the "F-D-C" Monthly OTC Index, only Cetus (down 1-3/4 to 24-3/4) and Damon Biotech (down 3/8 to 7-3/4) lost ground. After frenetic trading activity in the last quarter of 1985 and a 200%-plus price gain in 1985, Cetus may have been ready for a market correction. Centocor and Damon Biotech are two of twelve firms appearing on the Monthly Index for the first time. Joining the two monoclonal antibody companies in the Diversified Component are two other biotech firms, Integrated Genetics (up 1-1/2 to 6-3/4) and Moleculon Biotech (up 1/2 to 4), along with the Swedish drug manufacturer, Pharmacia (down 1-1/8 to 17-3/8). With the inclusion of the Irish firm Elan (unchanged at 12-1/2) on the Pharmaceutical Component, along with Pharmacia, the number of foreign-based firms on the Index is now up to five. Glaxo (up 1/8 to 12-1/4), Beecham (up 1/8 to 5-1/4) and Teva (down 1/8 to 3-3/8) comprise the rest of the foreign contingent. Elan is one of six new companies on the Pharmaceutical Component. Biotech firms Amgen (up 3/4 to 14-1/4), California Biotech (up 3-1/2 to 16-1/2) and Chiron (up 1-1/8 to 13-7/8) also make their Index debut, as do the drug delivery technology firm Pharmacontrol (down 7/8 to 7-3/8) and the basic research/drug receptor technology company Nova (up 1-1/2 to 8-1/4). Drug Systems (up 1/4 to 4-7/8) is the lone addition to the Chain Component, joining Begley (up 1/2 to 16-3/4) and Medicine Shoppe (down 2 to 22). Overall, Index issues performed well in the January market, with gainers outnumbering losers better than two to one. The Composite's 1.6% gain to 255, was in direct contrast to the Standard & Poors 400 average, which declined a fractional .6% to 233.28. A strong wholesaler group, paced by Alco Health Services (up 4 to 19-1/2), led all other components with a 9.2% advance. Chart omitted.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.
